Yesterday, Nov. 18, 2015, 127 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $235.29 to $228,091,773.00.

Highlighted Stocks Traded by Insiders:

Quantum (QTM) - FREE Research Report

Britts William C, who is SVP, Worldwide Sales & Mktg. at Quantum, bought 40,000 shares at $0.85 on Nov. 18, 2015. Following this transaction, the SVP, Worldwide Sales & Mktg. owned 1.2 million shares meaning that the stake was boosted by 3.43% with the 40,000-share transaction.

The shares most recently traded at $0.82, down $0.03, or 3.22% since the insider transaction. Historical insider transactions for Quantum go as follows:

  • 4-Week # shares bought: 125,000
  • 4-Week # shares sold: 170,000
  • 12-Week # shares bought: 125,000
  • 12-Week # shares sold: 170,000
  • 24-Week # shares bought: 143,181
  • 24-Week # shares sold: 170,000

The average volume for Quantum has been 1.6 million shares per day over the past 30 days. Quantum has a market cap of $205.8 million and is part of the technology sector and computer hardware industry. Shares are down 53.47% year-to-date as of the close of trading on Wednesday.

Quantum Corporation provides scale-out storage, archive, and data protection solutions for small businesses to major enterprises in the Americas, Europe, and the Asia Pacific. The company has a P/E ratio of 14.7. Currently, there are 4 analysts who rate Quantum a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on QTM - FREE

TheStreet Quant Ratings

rates Quantum as a

sell

. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and feeble growth in its earnings per share. Get the full

Quantum Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Pennant Park Investment Corporation (PNNT) - FREE Research Report

Efrat Aviv, who is CFO and Treasurer at Pennant Park Investment Corporation, bought 10,000 shares at $6.50 on Nov. 18, 2015. Following this transaction, the CFO and Treasurer owned 68,103 shares meaning that the stake was boosted by 17.21% with the 10,000-share transaction.

The shares most recently traded at $6.81, up $0.31, or 4.51% since the insider transaction. Historical insider transactions for Pennant Park Investment Corporation go as follows:

  • 4-Week # shares bought: 12,899
  • 12-Week # shares bought: 12,899
  • 24-Week # shares bought: 12,899

The average volume for Pennant Park Investment Corporation has been 506,400 shares per day over the past 30 days. Pennant Park Investment Corporation has a market cap of $483.8 million and is part of the financial sector and financial services industry. Shares are down 29.17% year-to-date as of the close of trading on Wednesday.

PennantPark Investment Corporation is a publicly listed business development firm specializing in direct and mezzanine investments in middle market companies. It invests in the form of mezzanine debt, senior secured loans, and equity investments. The stock currently has a dividend yield of 16.89%. The company has a P/E ratio of 4.0. Currently, there are 6 analysts who rate Pennant Park Investment Corporation a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PNNT - FREE

TheStreet Quant Ratings

rates Pennant Park Investment Corporation as a

hold

. The company's strengths can be seen in multiple areas, such as its revenue growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full

Pennant Park Investment Corporation Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

NxStage Medical (NXTM) - FREE Research Report

Moore Craig W, who is Director at NxStage Medical, sold 4,000 shares at $19.60 on Nov. 18, 2015. Following this transaction, the Director owned 93,046 shares meaning that the stake was reduced by 4.12% with the 4,000-share transaction.

The shares most recently traded at $19.54, down $0.06, or 0.31% since the insider transaction. Historical insider transactions for NxStage Medical go as follows:

  • 4-Week # shares bought: 10,150
  • 4-Week # shares sold: 9,973
  • 12-Week # shares bought: 10,150
  • 12-Week # shares sold: 19,733
  • 24-Week # shares bought: 10,150
  • 24-Week # shares sold: 41,328

The average volume for NxStage Medical has been 577,600 shares per day over the past 30 days. NxStage Medical has a market cap of $1.2 billion and is part of the health care sector and health services industry. Shares are up 10.15% year-to-date as of the close of trading on Wednesday.

NxStage Medical, Inc., a medical device company, develops, manufactures, and markets products for the treatment of kidney failure, fluid overload, and related blood treatments and procedures. Currently, there are 4 analysts who rate NxStage Medical a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on NXTM - FREE

TheStreet Quant Ratings

rates NxStage Medical as a

hold

. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full

NxStage Medical Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.